Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
is being developed for the treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). Post additional scrutinization, the FDA informed the company that the available clinical data from the phase III MSB-GVHD001 study of remestemcel-L is adequate to support the resubmission of the biologics license application (BLA) for remestemcel-L to treat pediatric patients with SR-aGVHD. Mesoblast is currently gearing up to file the BLA resubmission during the second quarter of 2024, seeking to address all remaining product characterization issues. Presently, there are also no approved therapies in the United States for patients under 12 years of age suffering from aGvHD, which provides MESO with a significant market opportunity, subject to the FDA approval of the regulatory filing for remestemcel-L in this indication. In the past year, shares of MESO have plunged 37% compared with the industry's 8.5% decline. Image Source: Zacks Investment Resear
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Repare Therapeutics appoints Steven Stein to its board of directors [Seeking Alpha]Seeking Alpha
- Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $92.00 to $84.00. They now have an "outperform" rating on the stock.MarketBeat
INCY
Earnings
- 2/13/24 - Beat
INCY
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/1/24 - Form 4
- INCY's page on the SEC website